Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

11 evidence topics · 13 sources

Summary

COMPASS has submitted a New Drug Application for COMP360 for TRD, which its press release defines as an inadequate response to two or more courses of antidepressants of adequate dose and duration. Guidelines that address psilocybin restrict it to research: the VA/DoD guideline recommends against psilocybin for MDD “outside of a research setting”, with very low confidence in the evidence; the CANMAT guideline update considers psilocybin-assisted psychotherapies “investigational treatments”; and a CANMAT task force recommends use primarily within clinical trials. The EMA guideline recommends starting psychedelic development in TRD and states that psychedelics need administration “in a controlled environment”. ICER's draft scope assesses psilocybin 25 mg in adults with MDD without psychotic features after two or more failed adequate antidepressant trials in the current episode, with esketamine, intravenous ketamine, and rTMS as comparators focusing on US outpatient settings. The company's November 2026 investor presentation states that dosing and monitoring will take place at a certified treatment center, and its quarterly release cites more than 8,500 treatment centers. The company described one or two initial administrations followed by episodic dosing per physician decision. Payer panel participants named head-to-head trials against esketamine or other active comparators as the most important evidence for coverage.

Anticipated care setting: certified interventional psychiatry treatment centers